Tonix Pharmaceuticals Holding Corp (nasdaq:TNXP) Share Price

Company Profile

Business description
Tonix Pharmaceuticals Holding Corp is a fully-integrated biopharmaceutical company commercializing and developing therapies for central nervous system (CNS) disorders, immunology, infectious diseases, and rare diseases. Its portfolio consists of commercial, development and discovery-stage programs, TONMYA, an approved treatment for fibromyalgia, as well as marketed acute migraine products Zembrace SymTouch and Tosymra. The company is conducting clinical trials to evaluate TONMYA for additional indications such as depressive disorder and acute stress disorder. It is also advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection.
Contact
200 Connell Drive
Suite 3100
Berkeley HeightsNJ07928
USA
T: +1 862 799-8599
E: [email protected]
https://www.tonixpharma.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
142

Recommended

Wide moat Eli Lilly receives FDA approval for obesity pill.

Karen Andersen, CFA | 02 April 2026

These companies are our favourite choices for investors wanting to boost Aussie equity exposure.

Simonelle Mody | 02 April 2026

OpenAI, Anthropic, and Databricks are expected to go public this year at massive valuations.

Harrison Rolfes | 02 April 2026

Index	Last price	Change	% Change
All Ordinaries	8,774.90	124.80	-1.40%
CAC 40	7,962.39	0.00	0.00%
DAX 40	23,168.08	130.81	-0.56%
Dow JONES (US)	46,504.67	61.07	-0.13%
FTSE 100	10,436.29	71.50	0.69%
HKSE	25,116.53	177.50	-0.70%
NASDAQ	21,879.18	38.23	0.18%
Nikkei 225	53,123.49	660.22	1.26%
NZX 50 Index	12,902.15	76.28	0.59%
S&P 500	6,582.69	7.37	0.11%
S&P/ASX 200	8,579.50	105.50	-1.21%
SSE Composite Index	3,919.29	29.27	-0.74%